The Ebola Vaccination Research Partnership (PREVAC) recently launched a new project called PREVAC-UP, which will assess three Ebola vaccine regimes for five years after vaccination.
The study will assess a number of factors within these treatments: their long-term safety, the durability of immune responses to them, and the effect of other immunizations on the immune response to vaccination. Vaccines will be assessed through integrated statistical analysis of the immune response.
“This program is expected to have a significant impact on the prevention and control of Ebola in adults and children in Africa,” said Dr. Yazdan Yazdanpanah, PREVAC Chief Investigator. “The study will strengthen the scientific potential of developing and evaluating new vaccines in sub-Saharan Africa.”
Such work was highlighted for PREVAC when the two worst Ebola outbreaks began in history in the last decade. There is a continuing outbreak in the Democratic Republic of Congo, which killed 2,200 people and infected more than 3,300, and the West African outbreak in 2014-2016, which ended with 28,600 cases and 11,325 people died, according to the Control Centers. and Disease Prevention.
These tests encouraged drug trials which should see results from PREVAC later this year, which focused on World Health Organization (WHO) pre-qualified drugs developed by Merck, Sharp & Dohme, Corp and a two-dose vaccination regime. created by Janssen Vaccines & Prevention BV and Nordic Bavarian. These studies tracked safety and immunity over 12 months, using three different vaccination strategies taken on the vaccines. In total, 2,802 participants were enrolled in the main phase.
PREVAC-UP is funded by the European Union and Developing Countries Clinical Trial Partnership, under the European Union, but is working with host countries, Liberia, Sierra Leone, Guinea and Mali. It was also funded by Inserm, the National Institute for Allergy and Infectious Diseases, London School of Hygiene & Tropical Medicine, and the College of Medicine and Related Health Sciences, University of Sierra Leone.